Rankings / Hormones & Endocrine

Elinzanetant (Lynkuet)

Hormones & Endocrine · NK1/NK3 dual receptor antagonist (non-hormonal)

Tier A-

Reviewed by Read Off Label · Last reviewed · How we grade

methylationprescription
7.6 / 10
Tier A-
Ev 8 Bn 8 Sf 7

Bottom line

Read Off Label grades Elinzanetant (Lynkuet) as A- (7.6/10) based on strong evidence, high benefit magnitude, and a low-med-risk safety profile.

Bayer; brand Lynkuet.

Studied, labeled, or reported-use context: 120 mg PO once daily — Rx; not individualized guidance.

What the evidence says

Bayer; brand Lynkuet. The NK1 component produced sleep and mood effects in trials; unlike fezolinetant labeling the cited elinzanetant safety analysis does not require liver monitoring. Also being studied for endocrine-therapy-induced hot flashes in breast cancer survivors.

Mechanism

Dual neurokinin 1 + neurokinin 3 receptor antagonist; the NK1 component additionally improves sleep and mood vs fezolinetant's NK3-only mechanism; same hypothalamic KNDy-circuit normalization for VMS

Studied, labeled, or reported dose & route

120 mg PO once daily

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Elinzanetant (Lynkuet)'s effects?
Read Off Label rates the evidence for Elinzanetant (Lynkuet) as Strong and the benefit magnitude as high, producing an overall grade of A- (7.6/10). Bayer; brand Lynkuet.
What safety findings are reported for Elinzanetant (Lynkuet)?
Elinzanetant (Lynkuet) has a low-med risk profile in the database. Low-Med (no liver monitoring required per OASIS pooled liver-safety analysis 2026; somnolence/headache most common AEs) Legal status: Rx (approved EMA/several countries 2025; FDA filing in progress).
What doses or routes are reported for Elinzanetant (Lynkuet)?
120 mg PO once daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Elinzanetant (Lynkuet) work?
Dual neurokinin 1 + neurokinin 3 receptor antagonist; the NK1 component additionally improves sleep and mood vs fezolinetant's NK3-only mechanism; same hypothalamic KNDy-circuit normalization for VMS

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.